Signatur Biosciences

Recent Finacing

Seed

Recent Raise

$7M

Signatur Biosciences develops OncoSignatur Breast, a decentralized prognostic qPCR test using proprietary PCRchitectur to run a single‑reaction workflow on standard qPCR machines for same‑day hospital and clinical-lab use.

Founded 2022

New York, United States

1-10

Private

signatur.bio

Highlights

Focus Areas

Biopharma

Biotechnology

Medical Device

Recent Investors

T

Financials

$7M

Total Raised

1

Funding round

2

Investors

Team

Upgrade to view the team

See the team members at Signatur Biosciences.